Renaissance Capital logo

Hemoglobin Oxygen Therapeutics Filed, US Offering, Removed, Nasdaq: HOTI

Relaunching hemoglobin-based oxygen carriers for human and veterinary use.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a biotechnology company focused on the development, manufacture, and commercialization of a proprietary technology platform for oxygen-carrying solutions that address critical unmet medical needs in both human and veterinary medicine. Using our patents, proprietary technology and know-how, we develop and sell products that, under certain conditions, are a possible alternative to blood transfusions to deliver oxygen to organs and tissues. Through numerous clinical studies, our products have been shown to address many of the current limitations that exist for blood transfusion. These include the limited shelf life of blood, logistical challenges of typing/cross-matching, delays in testing for pathogens, and blood shortages during times of high need and/or insufficient donations. We have significant experience gained through extensive pre-clinical and clinical testing of these products, which have a well-understood and extensively documented safety and efficacy profile.
more less
IPO Data
IPO File Date 04/26/2022
Offer Price
Price Range n/a
Offer Shares (mm) n/a
Deal Size ($mm) $30
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range n/a
Offer Shares (mm) n/a
Deal Size ($mm) $30
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
WestPark Capital
Company Data
Headquarters Souderton, PA, United States
Founded 1984
Employees at IPO 10
Website www.hbo2therapeutics.com

Hemoglobin Oxygen Therapeutics (HOTI) Performance